Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population

Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population

Objective: We aimed to establish a population pharmacokinetic (PPK) model for isoniazid (INH) and its major metabolite Acetylisoniazid (AcINH) in healthy Chinese participants and tuberculosis patients and assess the role of the NAT2 genotype on the transformation of INH to AcINH. We also sought to e...

Full description

Bibliographic Details
Main Authors:	Bing Chen, Hao-Qiang Shi, Meihua Rose Feng, Xi-Han Wang, Xiao-Mei Cao, Wei-Min Cai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Pharmacology
Subjects:	isoniazid acetylisoniazid population pharmacokinetics N-acetyltransferase 2 genetic polymorphism pharmacodynamics
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.932686/full

Similar Items

Pharmacokinetic assessment of isoniazid and acetylisoniazid in carbon tetrachloride-induced liver injury model in Wistar rats
by: Swati Sharma, et al.
Published: (2023-01-01)

NAT2 gene polymorphisms and plasma isoniazid concentration in Vietnamese tuberculosis patients
by: Anh Tuan Le, et al.
Published: (2019-11-01)

NAT2 Genotype and Isoniazid Medication in Children
by: Klaus Golka, et al.
Published: (2016-09-01)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
by: Roganović Maša, et al.
Published: (2021-01-01)

Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis
by: Soedarsono Soedarsono, et al.
Published: (2022-04-01)

Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
by: Shijia Liu, et al.
Published: (2017-07-01)

Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol
by: Ebrahim Salehifar, et al.
Published: (2017-06-01)

Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes
by: Mark A. Doll, et al.
Published: (2017-07-01)

Pharmacokinetics of isoniazid in Wistar rats exposed to ethanol
by: Taísa Busaranho Franchin, et al.
Published: (2023-01-01)

Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of <i>Mycobacterium tuberculosis</i> Infection
by: Laura Sibley, et al.
Published: (2022-11-01)

Isoniazid metabolism and hepatotoxicity
by: Pengcheng Wang, et al.
Published: (2016-09-01)

Ivermectin: Difficulties in resolving pharmacokinetic and pharmacodynamic relationships in onchocerciasis
by: E N Shu, et al.
Published: (2004-01-01)

Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
by: Dong-Seok Lee, et al.
Published: (2018-04-01)

Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin
by: A. A. Kachanova, et al.
Published: (2021-03-01)

Pharmacodynamics and Pharmacokinetics of Injectable Pimobendan and Its Metabolite, O-Desmethyl-Pimobendan, in Healthy Dogs
by: Poonavit Pichayapaiboon, et al.
Published: (2021-08-01)

Alfaxalone population pharmacokinetics in the rat: Model application for pharmacokinetic and pharmacodynamic design in inbred and outbred strains and sexes
by: Kate White, et al.
Published: (2022-12-01)

Pharmacodynamics and pharmacokinetics of nalbuphine in xylazine‑sedated horses
by: Amal Hammad, et al.
Published: (2023-05-01)

Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia
by: Rong-Rong Li, et al.
Published: (2019-05-01)

Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository
by: Ju G, et al.
Published: (2024-03-01)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
by: Alexandre Le Marouille, et al.
Published: (2021-10-01)

Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban
by: Xiao-Qin Liu, et al.
Published: (2023-02-01)

Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation
by: Maria Kipourou, et al.
Published: (2023-02-01)

Pharmacokinetic/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation
by: Pan Ma, et al.
Published: (2023-06-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

The Influence of NAT2 Genotypes on Isoniazid Plasma Concentration of Pulmonary Tuberculosis Patients in Southern Thailand
by: Usanee Ungcharoen, et al.
Published: (2020-12-01)

Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar
by: Jesmin Permala Lohy Das, et al.
Published: (2018-03-01)

Pharmacokinetic and pharmacodynamic correlation of plasma concentrations and blood pressure in hypertensive patients: A study
by: Mahvash Iram, et al.
Published: (2016-01-01)

The pharmacokinetics and pharmacodynamics of fentanyl administered via transdermal patch in horses
by: Rachel A. Reed, et al.
Published: (2024-03-01)

Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia
by: Sutep Jaruratanasirikul, et al.
Published: (2015-02-01)

Pharmacokinetic and Pharmacodynamic Properties of Rosmarinic Acid in Rat Cholestatic Liver Injury
by: Jianbin Min, et al.
Published: (2018-09-01)

Pharmacodynamics and pharmacokinetics interaction between nefopam and tramadol in the broiler chicks model
by: Yaareb J. Mousa, et al.
Published: (2022-04-01)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
by: Yaxin Fan, et al.
Published: (2022-06-01)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
by: Raghunandan Reddy Kura, et al.
Published: (2018-05-01)

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
by: Yuancheng Chen, et al.
Published: (2023-02-01)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
by: Hirsh Elhence, et al.
Published: (2022-12-01)

Corrigendum: Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects
by: Ying Zhou, et al.
Published: (2019-03-01)

COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: O. P. Bobrova, et al.
Published: (2015-12-01)

Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy
by: Yutaka Fukaya, et al.
Published: (2023-01-01)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)